Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-hepatic oxaliplatin plus systemic gemcitabine/capecitabine ± cetuximab for non-resectable liver metastases from cholangiocarcinoma
2010-020188-19Phase 2Terminated
- Sponsor
- Oncology Department
- Start
- Jun 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, gemcitabine, capecitabine and cetuximab in cholangiocarcinoma (CCA) (2 arms), sponsored by Oncology Department. Primary endpoint: Response rate. Started Jun 2010; status: terminated.
02
Drugs
oxaliplatingemcitabinecapecitabinecetuximab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2010-020188-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020188-19.